A Great News! But…Would This ‘Golden Goose’ Lay Golden Eggs?

On December 9, 2014, international media flashed across the world a great news item from the Indian pharma industry: “The first biosimilar of the world’s top-selling medicine Humira (adalimumab) of AbbVie has been launched in India by Zydus Cadila.” This … Continue reading

“Make in India…Sell Anywhere in The World”: An Indian Pharma Perspective

In his Independent Day speech from the ramparts of the Red Fort on August 15, 2014, Indian Prime Minister Modi gave a clarion call to all investors of the world, “Come, make in India”, “Come, manufacture in India”, “Sell in … Continue reading

Drugs From The Same Indian Plant: Safe For Europe, Unsafe For America, Why?

Good number of stories on US-FDA banning several drug manufacturing facilities of major domestic players of India over serious quality related issues, have been doing the rounds since about a year and almost at a regular interval. The quagmire has … Continue reading

Astronomical Prices of Patented Cancer Drugs: A Solution in Sight?

Astronomical prices of patented anti-cancer dugs have become a subject of great concern not just in India. It is becoming an issue across the world. After issuing the first ever Compulsory License (CL) for Nexavar of Bayer in India, the … Continue reading

The top 10 environment polluters of the world should now transform themselves into the top 10 saviours of the world from the disaster of Climate Change

Global awareness dawned early: After World War the second, various types of atmospheric pollution started drawing increasing public attention in the western world, both in the USA and Europe. In Europe, the incidence of London’s ‘Great Smog’ in 1952 initiated the process … Continue reading

Europe: now emerging as a more preferred market for the domestic Indian Pharmaceutical Industry

Since almost last 30 years the Pharmaceutical Industry of India has been a net foreign exchange earner. Deutche Bank Researchindicates that over the last ten years the export surplus has widened from EUR 370 million to EUR 2 billion.Around 80% … Continue reading